Shares of Koninklijke Philips (NYSE:PHG – Get Free Report) have received a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company.
PHG has been the subject of several research reports. StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research report on Monday, July 15th. Jefferies Financial Group upgraded Koninklijke Philips from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 29th.
View Our Latest Stock Report on PHG
Institutional Inflows and Outflows
Koninklijke Philips Stock Up 2.2 %
NYSE PHG opened at $27.08 on Tuesday. Koninklijke Philips has a 52-week low of $19.49 and a 52-week high of $32.91. The firm has a 50-day moving average price of $30.72 and a 200 day moving average price of $28.05. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.74.
Koninklijke Philips Company Profile
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
Further Reading
- Five stocks we like better than Koninklijke Philips
- What is a Low P/E Ratio and What Does it Tell Investors?
- Intel: Is Now the Time to Be Brave?Â
- P/E Ratio Calculation: How to Assess Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 3 Monster Growth Stocks to Buy Now
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.